Covered recipient · General Payments record
FARSHID DAYYANI
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$230,104.67
333 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $124,670.25 | 46 |
| Honoraria | $45,000.00 | 10 |
| Travel and Lodging | $33,318.41 | 163 |
| Consulting Fee | $20,250.00 | 11 |
| Food and Beverage | $6,866.01 | 103 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Sirtex Medical Inc | $61,021.83 | 120 |
| Exelixis Inc. | $55,051.27 | 58 |
| EISAI INC. | $50,407.83 | 80 |
| Ipsen Biopharmaceuticals, Inc | $31,644.86 | 32 |
| Amgen Inc. | $19,284.84 | 32 |
| Foundation Medicine, Inc. | $10,750.00 | 6 |
| Ipsen Bioscience Inc | $1,720.02 | 3 |
| Genentech USA, Inc. | $126.78 | 1 |
| Array BioPharma Inc. | $97.24 | 1 |
Page 5 of 7; records 201–250 of 333 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
FARSHID DAYYANI
NPI 1376710434 · CMS profile ID 62653
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
ORANGE, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 7; records 201–250 of 333 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1376710434?year=2019&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- FARSHID DAYYANI, NPI 1376710434, CMS profile ID 62653. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 333 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376710434?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). FARSHID DAYYANI, NPI 1376710434, CMS profile ID 62653. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 333 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376710434?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- FARSHID DAYYANI, NPI 1376710434, CMS profile ID 62653, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 7; records 201–250 of 333 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1376710434?year=2019&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
333 matching records · $230,104.67 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–250 of 333.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Sirtex Medical Inc | $21.38 | 04/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664715 | CMS |
| Sirtex Medical Inc | $4,500.00 | 04/24/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664757 | CMS |
| Sirtex Medical Inc | $121.53 | 04/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698370105 | CMS |
| Sirtex Medical Inc | $701.04 | 04/19/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664575 | CMS |
| Sirtex Medical Inc | $9.00 | 04/19/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664577 | CMS |
| Sirtex Medical Inc | $329.77 | 04/19/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664619 | CMS |
| Sirtex Medical Inc | $20.00 | 04/19/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664645 | CMS |
| Sirtex Medical Inc | $15.66 | 04/19/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664647 | CMS |
| Sirtex Medical Inc | $17.96 | 04/19/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664649 | CMS |
| Sirtex Medical Inc | $7.34 | 04/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664709 | CMS |
| Sirtex Medical Inc | $15.04 | 04/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664711 | CMS |
| Sirtex Medical Inc | $12.97 | 04/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664713 | CMS |
| Foundation Medicine, Inc. | $3,000.00 | 04/18/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675548169 | CMS |
| Eisai Inc. | $1,000.00 | 04/17/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703229941 | CMS |
| Eisai Inc. | $109.63 | 04/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703229995 | CMS |
| Eisai Inc. | $3,125.00 | 04/17/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703229997 | CMS |
| Eisai Inc. | $227.59 | 04/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703229999 | CMS |
| Eisai Inc. | $617.16 | 04/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703230001 | CMS |
| Eisai Inc. | $293.41 | 04/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703230003 | CMS |
| Eisai Inc. | $11.63 | 04/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703230005 | CMS |
| Eisai Inc. | $16.24 | 04/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703230007 | CMS |
| Eisai Inc. | $20.00 | 04/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703230009 | CMS |
| Sirtex Medical Inc | $141.12 | 04/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 698370097 | CMS |
| Sirtex Medical Inc | $4,500.00 | 04/11/2019 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664755 | CMS |
| Amgen Inc. | $15.45 | 04/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662342447 | CMS |
| Amgen Inc. | $20.00 | 04/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662342449 | CMS |
| Amgen Inc. | $20.45 | 04/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662342455 | CMS |
| Amgen Inc. | $32.78 | 04/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662342457 | CMS |
| Amgen Inc. | $4.00 | 04/09/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662342459 | CMS |
| Eisai Inc. | $625.00 | 04/08/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703229957 | CMS |
| Amgen Inc. | $2,600.00 | 04/07/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662342451 | CMS |
| Amgen Inc. | $866.00 | 04/07/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662342453 | CMS |
| Sirtex Medical Inc | $636.99 | 03/29/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664569 | CMS |
| Sirtex Medical Inc | $9.00 | 03/29/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664571 | CMS |
| Sirtex Medical Inc | $62.00 | 03/29/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664573 | CMS |
| Eisai Inc. | $122.28 | 03/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703230029 | CMS |
| Eisai Inc. | $3,125.00 | 03/28/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703230031 | CMS |
| Eisai Inc. | $18.56 | 03/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703230033 | CMS |
| Eisai Inc. | $4.00 | 03/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703230035 | CMS |
| Foundation Medicine, Inc. | $2,000.00 | 03/28/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 675548167 | CMS |
| Amgen Inc. | $120.81 | 03/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662342441 | CMS |
| Amgen Inc. | $266.07 | 03/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662342445 | CMS |
| Sirtex Medical Inc | $80.06 | 03/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664641 | CMS |
| Sirtex Medical Inc | $20.00 | 03/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664643 | CMS |
| Sirtex Medical Inc | $12.96 | 03/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664703 | CMS |
| Sirtex Medical Inc | $12.48 | 03/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664705 | CMS |
| Sirtex Medical Inc | $6.19 | 03/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704664707 | CMS |
| Exelixis Inc. | $5,280.00 | 03/21/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 686542849 | CMS |
| Eisai Inc. | $35.96 | 03/19/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703229939 | CMS |
| Eisai Inc. | $95.37 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 703229981 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,721,730.22 | 189 |
| PY2024 | Principal investigator | $2,129,801.10 | 84 |
| PY2023 | Principal investigator | $1,178,329.48 | 52 |
| PY2022 | Recipient | $400.01 | 1 |
| PY2022 | Principal investigator | $1,158,103.64 | 40 |
| PY2021 | Principal investigator | $2,063,941.97 | 51 |
| PY2020 | Recipient | $8,306.48 | 5 |
| PY2020 | Principal investigator | $1,850,901.21 | 79 |
| PY2019 | Principal investigator | $1,109,962.19 | 111 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
189 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $615.12 | 12/31/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults with Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1202425046 |
| Principal investigator 1 | Genentech, Inc. | $26,208.00 | 12/29/2025 | Covered Recipient Teaching Hospital Fountain Valley Reg Medical Center | PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC | No dispute reported | 06/30/2026 | 1211544369 |
| Principal investigator 1 | Genentech, Inc. | $828.00 | 12/05/2025 | Covered Recipient Teaching Hospital Fountain Valley Reg Medical Center | PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC | No dispute reported | 06/30/2026 | 1211544373 |
| Principal investigator 1 | ABBVIE INC. | $578.53 | 12/04/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202425021 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,010.00 | 12/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737898 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,020.00 | 12/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737900 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,010.00 | 12/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737902 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $528.00 | 12/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737904 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 12/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737906 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 12/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737896 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16,896.00 | 11/30/2025 | Non-covered Recipient Entity University Of California Irvine | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220650237 |
| Principal investigator 1 | Amgen Inc. | $25,091.00 | 11/25/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301) | No dispute reported | 06/30/2026 | 1246638568 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $288.49 | 11/19/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737908 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.64 | 11/19/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737910 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $199.80 | 11/19/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737912 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 11/19/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737914 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $122.14 | 11/19/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737916 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.00 | 11/19/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737918 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20.44 | 11/19/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737920 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,571.00 | 11/18/2025 | Non-covered Recipient Entity Uci Health Chao Family Comprehensive Cancer Center | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 1176546185 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,500.00 | 11/14/2025 | Non-covered Recipient Entity SABAI LLC | A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma | No dispute reported | 06/30/2026 | 1185549213 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $15,496.00 | 11/14/2025 | Non-covered Recipient Entity Uci Health Chao Family Comprehensive Cancer Center | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 1176546187 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $18,194.00 | 11/13/2025 | Non-covered Recipient Entity Uci Health Chao Family Comprehensive Cancer Center | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 1176546189 |
| Principal investigator 1 | Exelixis Inc. | $691.20 | 11/07/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222378220 |
| Principal investigator 1 | ABBVIE INC. | $2,403.07 | 11/05/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202424984 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $17,690.00 | 11/05/2025 | Covered Recipient Teaching Hospital Ronald Reagan Ucla | Durvalumab or Placebo in Combination With Gemcitabine Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer TOPAZ-1 | No dispute reported | 06/30/2026 | 1185549203 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,020.00 | 11/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737874 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,042.00 | 11/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737876 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $528.00 | 11/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737878 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 11/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737880 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.00 | 11/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737882 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.00 | 11/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737884 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $33.00 | 11/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737886 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $33.00 | 11/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737888 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.00 | 11/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737890 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,054.00 | 11/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737892 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,537.00 | 11/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737894 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 11/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737872 |
| Principal investigator 1 | ABBVIE INC. | $8,745.00 | 10/31/2025 | Covered Recipient Teaching Hospital LANGLEY PORTER PSYCHIATRIC HOSPITAL | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) | No dispute reported | 06/30/2026 | 1202414308 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9,380.00 | 10/31/2025 | Non-covered Recipient Entity University Of California Irvine | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220650225 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7,993.88 | 10/31/2025 | Non-covered Recipient Entity University Of California Irvine | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220650227 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11,663.52 | 10/31/2025 | Non-covered Recipient Entity University Of California Irvine | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220650229 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $17,443.80 | 10/31/2025 | Non-covered Recipient Entity University Of California Irvine | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220650231 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40,332.60 | 10/31/2025 | Non-covered Recipient Entity University Of California Irvine | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220650233 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $66,931.92 | 10/31/2025 | Non-covered Recipient Entity University Of California Irvine | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220650235 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $61,395.64 | 10/31/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220997784 |
| Principal investigator 1 | Genentech, Inc. | $13,453.20 | 10/22/2025 | Covered Recipient Teaching Hospital Fountain Valley Reg Medical Center | PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC | No dispute reported | 06/30/2026 | 1211544365 |
| Principal investigator 1 | ABBVIE INC. | $22,912.56 | 10/17/2025 | Covered Recipient Teaching Hospital LANGLEY PORTER PSYCHIATRIC HOSPITAL | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) | No dispute reported | 06/30/2026 | 1202414300 |
| Principal investigator 1 | PFIZER INC. | $1,327.92 | 10/14/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228712606 |
| Principal investigator 1 | ABBVIE INC. | $2,403.07 | 10/09/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202424913 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,051.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737840 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737842 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737844 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,942.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737846 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $33.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737848 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737850 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,942.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737852 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $347.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737854 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $347.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737856 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,042.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737858 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $528.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737860 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737862 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,128.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737864 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,110.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737866 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,621.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737868 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $528.00 | 10/02/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737870 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 10/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737838 |
| Principal investigator 1 | Genentech, Inc. | $12,091.00 | 10/01/2025 | Covered Recipient Teaching Hospital Langley Porter Psychiatric Hospital | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211548157 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $71,628.25 | 09/30/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220997782 |
| Principal investigator 1 | Exelixis Inc. | $1,278.00 | 09/19/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222378216 |
| Principal investigator 1 | ABBVIE INC. | $46,209.68 | 09/12/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) | No dispute reported | 06/30/2026 | 1202424523 |
| Principal investigator 1 | ABBVIE INC. | $11,513.99 | 09/05/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202424895 |
| Principal investigator 1 | Exelixis Inc. | $1,330.20 | 09/05/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222378218 |
| Principal investigator 1 | ABBVIE INC. | $4,245.09 | 09/04/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202424883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,054.00 | 09/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737814 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,537.00 | 09/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737816 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,022.00 | 09/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737818 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,648.00 | 09/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737820 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $420.00 | 09/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737822 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.00 | 09/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737824 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,054.00 | 09/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737826 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,537.00 | 09/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737828 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,058.00 | 09/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737830 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,537.00 | 09/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737832 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,110.00 | 09/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737834 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,621.00 | 09/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737836 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 09/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737774 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24,681.25 | 08/31/2025 | Non-covered Recipient Entity University Of California Irvine | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220650223 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $41,499.47 | 08/27/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | Fruquintinib | No dispute reported | 06/30/2026 | 1223270376 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,240.00 | 08/27/2025 | Covered Recipient Teaching Hospital UC DAVIS MEDICAL CENTER | Fruquintinib | No dispute reported | 06/30/2026 | 1223270378 |
| Principal investigator 1 | ABBVIE INC. | $578.53 | 08/06/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202424843 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737772 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,648.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737778 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,942.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737780 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $347.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737782 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,648.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737784 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,022.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737786 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,128.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737788 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $420.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737790 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737792 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,942.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737794 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $347.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737796 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,022.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737798 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,128.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737800 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,537.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737802 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6,110.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737804 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,621.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737806 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $420.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737808 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $106.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737810 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.00 | 08/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737812 |
| Principal investigator 1 | Exelixis Inc. | $691.20 | 07/18/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222378214 |
| Principal investigator 1 | ABBVIE INC. | $13,173.20 | 07/08/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202424762 |
| Principal investigator 1 | ABBVIE INC. | $4,806.14 | 07/02/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202424736 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 07/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737776 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,448.60 | 06/30/2025 | Non-covered Recipient Entity University Of California Irvine | A first-in-human Phase I, non-randomized, open-label, multi-center dose-escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6. | No dispute reported | 06/30/2026 | 1220650221 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $509.10 | 06/24/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737742 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.92 | 06/24/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737744 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $539.46 | 06/24/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737746 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 06/24/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737748 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $244.28 | 06/24/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737750 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $143.00 | 06/24/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737752 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.66 | 06/24/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737754 |
| Principal investigator 1 | PFIZER INC. | $5,083.18 | 06/23/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228830303 |
| Principal investigator 1 | Exelixis Inc. | $639.00 | 06/20/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222378212 |
| Principal investigator 1 | PFIZER INC. | $5,804.38 | 06/16/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228830296 |
| Principal investigator 1 | Genentech, Inc. | $8,264.10 | 06/11/2025 | Covered Recipient Teaching Hospital Fountain Valley Reg Medical Center | PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC | No dispute reported | 06/30/2026 | 1211544351 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 06/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737734 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 05/27/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737736 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.00 | 05/27/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737738 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.84 | 05/27/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737740 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $67.88 | 05/27/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737770 |
| Principal investigator 1 | Genentech, Inc. | $22,374.00 | 05/21/2025 | Covered Recipient Teaching Hospital Fountain Valley Reg Medical Center | PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC | No dispute reported | 06/30/2026 | 1211544356 |
| Principal investigator 1 | Exelixis Inc. | $1,969.20 | 05/16/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222378208 |
| Principal investigator 1 | Genentech, Inc. | $3,834.00 | 05/16/2025 | Covered Recipient Teaching Hospital Fountain Valley Reg Medical Center | PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC | No dispute reported | 06/30/2026 | 1211544360 |
| Principal investigator 1 | ABBVIE INC. | $21,424.66 | 05/14/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202424698 |
| Principal investigator 1 | ABBVIE INC. | $22,570.61 | 05/14/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202424703 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 05/13/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228827135 |
| Principal investigator 1 | PFIZER INC. | $43,996.68 | 05/13/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228827141 |
| Principal investigator 1 | PFIZER INC. | $10,940.00 | 05/12/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228825863 |
| Principal investigator 1 | PFIZER INC. | $43,996.68 | 05/12/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228825866 |
| Principal investigator 1 | Exelixis Inc. | $5,912.00 | 05/09/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222378206 |
| Principal investigator 1 | ABBVIE INC. | $23,311.31 | 05/08/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202424690 |
| Principal investigator 1 | ABBVIE INC. | $10,358.48 | 05/07/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202424679 |
| Principal investigator 1 | Exelixis Inc. | $77,084.79 | 05/05/2025 | Covered Recipient Teaching Hospital Uci Medical Center | Phase 2 Study of Cabozantinib Combined With Ipilimumab/Nivolumab and Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC) Who Are Not Candidates for Curative Intent Treatment | No dispute reported | 06/30/2026 | 1222378256 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $5,764.00 | 05/05/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastro | No dispute reported | 06/30/2026 | 1232927381 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 05/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737732 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $339.40 | 04/23/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737756 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 04/23/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737758 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.78 | 04/23/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737760 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 04/23/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737762 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $244.28 | 04/23/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737764 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 04/23/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737766 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.36 | 04/23/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737768 |
| Principal investigator 1 | Exelixis Inc. | $691.20 | 04/21/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222378210 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $20,090.84 | 04/18/2025 | Non-covered Recipient Entity Uci Health Chao Family Comprehensive Cancer Center | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 1176546183 |
| Principal investigator 1 | Amgen Inc. | $5,797.84 | 04/15/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression | No dispute reported | 06/30/2026 | 1246638570 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 04/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737730 |
| Principal investigator 1 | Exelixis Inc. | $12,970.00 | 03/31/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 1 Study of the Combination of Cabozantinib With Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Adenocarcinoma (mCRC) | No dispute reported | 06/30/2026 | 1222378226 |
| Principal investigator 1 | AstraZeneca UK Limited | $69,812.16 | 03/21/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 Combination with Durvalumab and Chemotherapy in Subjects with Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1185549209 |
| Principal investigator 1 | Exelixis Inc. | $1,330.20 | 03/21/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222378198 |
| Principal investigator 1 | Genentech, Inc. | $6,552.00 | 03/19/2025 | Covered Recipient Teaching Hospital Fountain Valley Reg Medical Center | PHASE Ib II STUDY EVALUATING THE EFFICACY AND SAFETY OF TREATMENT COMBINATIONS IN HCC MORPHEUS HCC | No dispute reported | 06/30/2026 | 1211544348 |
| Principal investigator 1 | Exelixis Inc. | $10,330.00 | 03/17/2025 | Covered Recipient Teaching Hospital Uci Medical Center | Phase 2 Study of Cabozantinib Combined With Pembrolizumab in Metastatic or Recurrent Gastric and Gastroesophageal Adenocarcinoma (mGC) | No dispute reported | 06/30/2026 | 1222378222 |
| Principal investigator 1 | ABBVIE INC. | $5,017.50 | 03/07/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | M24-052 - A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202424654 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $633,535.71 | 03/05/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase II Open-label Multi-centre Study to Evaluate Safety Tolerability Efficacy PK and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 182 | No dispute reported | 06/30/2026 | 1185549211 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 03/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737728 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $105,067.64 | 02/28/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation | No dispute reported | 06/30/2026 | 1185549215 |
| Principal investigator 1 | Exelixis Inc. | $6,550.04 | 02/24/2025 | Covered Recipient Teaching Hospital Uci Medical Center | Phase 2 Study of Cabozantinib Combined With Ipilimumab/Nivolumab and Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC) Who Are Not Candidates for Curative Intent Treatment | No dispute reported | 06/30/2026 | 1222378230 |
| Principal investigator 1 | Exelixis Inc. | $7,380.00 | 02/21/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222378204 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,750.00 | 02/13/2025 | Non-covered Recipient Entity CLINICAL BIOSAFETY SERVICES LLC | A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma | No dispute reported | 06/30/2026 | 1185549207 |
| Principal investigator 1 | ABBVIE INC. | $663.07 | 02/06/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | M24-052 - A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202424624 |
| Principal investigator 1 | PFIZER INC. | $21,059.34 | 02/03/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | A PHASE 1B2 OPENLABEL STUDY OF DISITAMAB VEDOTIN IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS | No dispute reported | 06/30/2026 | 1228831773 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737726 |
| Principal investigator 1 | AstraZeneca UK Limited | $338,016.02 | 01/29/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers (TOURMALINE) | No dispute reported | 06/30/2026 | 1185549199 |
| Principal investigator 1 | Exelixis Inc. | $10,481.00 | 01/29/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222378202 |
| Principal investigator 1 | Exelixis Inc. | $11,646.00 | 01/24/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer | No dispute reported | 06/30/2026 | 1222378200 |
| Principal investigator 1 | Exelixis Inc. | $21,316.81 | 01/21/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 1 Study of the Combination of Cabozantinib With Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Adenocarcinoma (mCRC) | No dispute reported | 06/30/2026 | 1222378224 |
| Principal investigator 1 | Exelixis Inc. | $15,620.28 | 01/21/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase 1 Study of the Combination of Cabozantinib With Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Adenocarcinoma (mCRC) | No dispute reported | 06/30/2026 | 1222378232 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $75,894.03 | 01/10/2025 | Covered Recipient Teaching Hospital Uci Medical Center | A Phase III,Randomized,Double Blind,Placebo Controlled,Multicenter,Global Study of Rilvegostomig in Combination with Chemotherapy as Adjuvant Treatment in Adult Participants After Resection of Biliary Tract Cancer with Curative Intent Artemide Biliary01 | No dispute reported | 06/30/2026 | 1185549201 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $176,253.58 | 01/10/2025 | Covered Recipient Teaching Hospital Uci Medical Center | This Phase II, open-label, uncontrolled, multicentre study evaluating the preliminary efficacy and safety of Volrustomig or Rilvegostomig as monotherapy (MONO) | No dispute reported | 06/30/2026 | 1185549205 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,960.00 | 01/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737708 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,500.00 | 01/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737710 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,442.00 | 01/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737712 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $22,750.00 | 01/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737714 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,320.00 | 01/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737716 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,750.00 | 01/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737718 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,240.00 | 01/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737720 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,275.00 | 01/03/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737722 |
| Principal investigator 1 | ABBVIE INC. | $2,403.07 | 01/02/2025 | Covered Recipient Teaching Hospital UCI MEDICAL CENTER | M24-052 - A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) | No dispute reported | 06/30/2026 | 1202424600 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 01/01/2025 | Non-covered Recipient Entity University Of California At Irvine Health Chao Family Comprehensive Cancer Center | Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) | No dispute reported | 06/30/2026 | 1220737724 |